Venlafaxine in the treatment of anxiety disorders

References

• Kessler R, McGonagle K, Zhao S etal Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the national comorbidity survey. Arch. Gen Psychiatry 51(1), 8–19 (1994).
   Google Scholar
• Kessler R, Sonnega A, Bromet E, Hughes M, Nelson C. Post-traumatic stress disorder in the national comorbidity survey. Arch. Gen. fiychiatry52 (12), 1048–1060 (1995).
   Google Scholar
• Robins L, Helzer J, Weissman M eta]. Lifetime prevalence of specific psychiatric disorders in three sites. Arch. Gen fiychiatry 41(10), 949–958 (1984).
   Google Scholar
• Ballenger J, Davidson J, Lecrubier Y eta]. Consensus statement on generalized anxiety disorder from the international consensus group on depression and anxiety. J. Gun. Psych. 62 (Suppl. 11), 53–58 (2001).
   Google Scholar
• Kessler R. Comorbidity of unipolar and bipolar depression with other psychiatric disorders in a general population survey. In: Comorbidity in Affective Disotylers. Tohen M (Ed.). Marcel Dekker Inc., NY, USA, 1–25, (1999).
   Google Scholar
• Melartin T, Rytsala H, Leskela U, Lestela- Mielonen P, Sokero T, Isometsa E. Current comorbidity of psychiatric disorders among DSM-IV major depressive disorder patients in psychiatric care in the Vantaa depression study. J. Gun. Psych. 63(2), 126–134 (2002).
   Google Scholar
• Greenberg P, Sisitsky T, Kessler R etal The economic burden of anxiety disorders in the 1990s. Clin. Psych. 60(7), 427–435 (1999).
   Google Scholar
• DuPont R, DuPont C, Rice D. Economic costs of anxiety disorders. In: Textbook of Anxiety Disotylers. Stein D, Hollander E (Eds). American Psychiatric Publishing, Washington DC, USA, 475–483, (2002).
   Google Scholar
• Guidelines for the Tratment of Anxiety Disotylets in Primary Care. Queen's Printer of Ontario, Toronto, Canada (2000).
   Google Scholar
• Ballenger J. Treatment of anxiety disorders to remission. J. Gila Psych. 62\(Suppl. 12), 5–9 (2001).
   Google Scholar
• •Good review of remission criteria for anxiety disorders.
   Google Scholar
• Rickets K, Rynn M. Pharmacotherapy of generalized anxiety disorder. J. Clin. Psych. 63\(Suppl. 14), 9–16 (2002).
   Google Scholar
• Rocca P, Fonzo V, Scotta M, Zanalda E, Ravizza L. Paroxetine efficacy in the treatment of generalized anxiety disorder. Acta Ptychiaty Scam/. 95(5), 444–450 (1997).
   PubMed Web of Science ®Google Scholar
• Muth E, Haskins J, Moyer J et al Antidepressant biochemical profile of the novel bicyclic compound wy-45,030, an ethyl cyclohexanol derivative. Biochem. Pharmacol 35, 4493–4497 (1986).
   Google Scholar
• Effexor XR (venlafaxine hydrochloride) product monograph, Wyeth laboratories. (2003).
   Google Scholar
• Muth E, Haskins J, Moyer J, Husbands G, Nielsen S, Sigg E. Antidepressant biochemical profile of the novel bicyclic compound wy-45,030, an ethyl cyclohexanol derivative. Biochem. Pharmacol 35(24), 4493–4497 (1986).
   Google Scholar
• Feighner J. Mechanism of action of antidepressant medications. J. Clin. Psych. 60\(Suppl. 4), 4–11 (1999).
   Google Scholar
• Smith D, Dempster C, Glanville J, Freemantle N, Anderson I. Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis. BE Psych. 180,396–404 (2002).
   PubMed Web of Science ®Google Scholar
• Nemeroff C, Entsuah A, Willard L, Demitrack M, Thase M. Venlafaxine and SSRIs: Pooled remission analysis. Presented at 156th APA Annual Meeting, CA, USA. 17–22 May (2003).
   Google Scholar
• Silverstone P, Salinas E. Efficacy of venlafaxine extended-release in patients with major depressive disorder and comorbid generalized anxiety disorder. J. Clin. Psych. 62(7), 523–529 (2001).
   Google Scholar
• Davidson J, Meoni P, Haudiquet V, Cantillon M, Hackett D. Achieving remission with venlafaxine and fluoxetine in major depression: its relationship to anxiety symptoms. Depress. Anxiety 16 (1), 4–13 (2002).
   Google Scholar
• Silverstone P Ravindran A. Once-daily venlafaxine extended -release (XR) compared with fluoxetine in outpatients with depression and anxiety. Venlafaxine XR 360 study group. Bych. 60(1), 22–28 (1999).
   Google Scholar
• ••Large, double-blind, placebo-controlled, trial with fluoxetine as active comparator in patients with depression and comorbid anxiety
   Google Scholar
• De Nayer A, Geerts S, Ruelens L eta]. Venlafaxine compared with fluoxetine in outpatients with depression and concomitant anxiety. Int. j Neuropsychopharmacol 5 (2), 115–120 (2002).
   Google Scholar
• •• Double-blind, placebo-controlled, trial with fluoxetine as active comparatorin patients with depression and comorbid anxiety
   Google Scholar
• Hackett D, Stein M, Mangano R, Pollack M. Long-term treatment of generalized social anxiety disorder with venlafaxine XR. Eur Call. Neumpsychophalmacol 13\(Suppl. 4), S380 (2003).
   Google Scholar
• •Long-term, double-blind, placebo-controlled, trial in patients with social anxiety disorder (SAD).
   Google Scholar
• Mangano R, Liebowitz M, Allgulander C. Comparison of venlafaxine extended-release and paroxetine in short-term treatment of SAD. Presented at 156th APA Annual Meeting, CA, USA. 17–22 May (2003).
   Google Scholar
• ••Report of two double-blind, placebo-controlled, trials with paroxetine as active comparator in patients with SAD.
   Google Scholar
• Davidson J, DuPont R, Hedges D, Haskins J. Efficacy, safety and tolerability of venlafaxine extended-release and buspirone in outpatients with generalized anxiety disorder. j Clin. Psych. 60(8), 528–535 (1999).
   Google Scholar
• Rickels K, Pollack M, Sheehan D, Haskins J. Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxiety disorder. Am. j Psych. 157(6), 968–974 (2000).
   PubMed Web of Science ®Google Scholar
• Gelenberg A, Lydiard R, Rudolph R, Aguiar L, Haskins J, Salinas E. Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: a 6-month randomized controlled trial. JAIVIA 283(23), 3082–3088 (2000).
   Google Scholar
• •• Large, long-term, double-blind, placebo-controlled, trial in patients with generalized anxiety disorder (GAD).
   Google Scholar
• Allgulander C, Hackett D, Salinas E. Venlafaxine extended-release (ER) in the treatment of generalised anxiety disorder: 24-week placebo-controlled dose-ranging study. Br. Psych. 179,15-22 (2001).
   Google Scholar
• •• Large, long-term, double-blind, placebo-controlled, trial in patients with GAD.
   Google Scholar
• Katz I, Reynolds C, Alexopoulos G, Hackett D. Venlafaxine ER as a treatment for generalized anxiety disorder in older adults: pooled analysis of five randomized placebo-controlled clinical trials. j Am. Ceriatr Soc. 50(1), 18–25 (2002).
   PubMed Web of Science ®Google Scholar
• Haudiquet V, Meoni P, Hackett D. Comparative efficacy of venlafaxine ER in male and female populations of GAD patients: a pooled analysis. Women Ment. Health (2001).
   Google Scholar
• Wan G, Zhang H. Pooled analysis of symptom-free days in generalized anxiety disorder. J. Eur Coll Aiumpsychophalmacol. 13\(Suppl. 4), S374 (2003).
   Google Scholar
• Montgomery S, Sheehan D, Meoni P, Haudiquet V, Hackett D. Characterization of the longitudinal course of improvement in generalized anxiety disorder during long-term treatment with venlafaxine XR. fisychiatr Res. 36(4), 209–217 (2002).
   PubMed Web of Science ®Google Scholar
• Ninan P, Hackett D, Haudiquet V. Response and remission in generalized anxiety disorder (GAD): how long should patients be treated? int. j Neuropsychopharmacol 5\(Suppl. 1), (2002).
   Google Scholar
• Meoni P, Salinas E, Brault Y, Hackett D. Pattern of symptom improvement following treatment with venlafaxine XR in patients with generalized anxiety disorder. j Clin. Psych. 62(11), 888–893 (2001).
   Google Scholar
• Davidson J, Lipschitz A, Musgnung J. Venlafaxine XR and sertraline in PTSD: a placebo-controlled study. j Eur Neuropsychopharmacol 13\(Suppl. 4), S380 (2003).
   Google Scholar
• •Large, double-blind, placebo-controlled, trial with sertraline as active comparator in patients with post-traumatic stress disorder.
   Google Scholar
• Davidson J. Venlafaxine XR versus sertraline and placebo in the acute treatment of PTSD. Presented at Anxiety DisoMer s Association of America, Toronto, Canada. 27–30 March (2003).
   Google Scholar
• Ahokas A, Bradwejn J, Emilien G, Whitaker T Treatment of panic disorder with venlafaxine XR. I Eur Coll Neuropsychopharmacol 13\(Suppl. 4), S377 (2003).
   Google Scholar
• Lepola U, Pollack M, Emilien G, Tzanis E, Whitaker T Venlafaxine XR and paroxetine in the short-term treatment of panic disorder. j Eur. Coll Neuropsychopharmacol 13\(Suppl. 4), S378 (2003).
   Google Scholar
• •Large, double-blind, placebo-controlled, trial with paroxetine as active comparator in patients with panic disorder.
   Google Scholar
• Mallick, Zhang H. Improvement in physical symptoms in select anxiety disorders. Presented at 156th APA Annual Meeting, San Francisco, CA, USA, May 17–22 (2003).
   Google Scholar
• Mallick R, Goo B. Quality of life and functionality in panic disorder improve with treatment. Presented at 156th APA Annual Meeting CA, USA. 17–22 May (2003).
   Google Scholar
• Albert U, Aguglia E, Mama G, Bogetto Venlafaxine versus clomipramine in the treatment of obsessive—compulsive disorder: a preliminary single-blind, 12-week, controlled study. j Clin. Psych. 63(11), 1004–1009 (2002).
   Google Scholar
• Denys D, Van der Wee N, Van Megen H, Westenberg H. Double-blind comparison of venlafaxine and paroxetine in obsessive—compulsive disorder. Int. J. Neuropsychopharmacol 5\(Suppl. 1), (2002).
   Google Scholar
• Denys D, Van Megen H, Westenberg H A double-blind comparison of venlafaxine and paroxetine in obsessive compulsive disorder. j Eur Coli. Neuropsychophannacol 12\(Suppl. 3), S342 (2002).
   Google Scholar
• •• Large, double-blind, placebo-controlled, trial with paroxetine as active comparator in patients with OCD.
   Google Scholar
• Fava M. Somatic symptoms, depression and antidepressant treatment. j Clin. Psych. 63(4), 305–307 (2002).
   Google Scholar
• Corruble E, Guelfi J. Pain complaints in depressed inpatients. Psychopathology33(6), 307–309 (2000).
   PubMed Web of Science ®Google Scholar
• Fossey M, Lydiard R. Anxiety and the gastrointestinal system. P.TchiatE Med. 8(3), 175–186 (1990).
   Google Scholar
• Lydiard B. Impact of baseline gastrointestinal (GI) symptoms on efficacy and tolerability of venlafaxine XR in patients with generalized anxiety disorder. Int. j Neuropsychophatmacol 5\(Suppl. 1), (2002).
   Google Scholar
• Adelman L, Adelman J, Von Seggem R, Mannix L. Venlafaxine extended -release (XR) for the prophylaxis of migraine and tension-type headache: a retrospective study in a clinical setting. Headache 40(7), 572–580 (2000).
   PubMed Web of Science ®Google Scholar
• Kunz N, Goli V, Entsuah R, Rudolph R. Effect of venlafaxine extended-release on diabetic neuropathic pain. New Research Abstracts. Annual Meeting of the American Psychiatric Association, Washington DC, USA (2000).
   Google Scholar
• Demitrack M, Kunz N, Entuah A. Evaluation of venlafaxine treatment for chronic pain. J. Eur Coli. Neumpsychophatmacol 13\(Suppl. 4), S452 (2003).
   Google Scholar
• Sindrup S, Bach F, Madsen C, Gram L, Jensen T Venlafaxine versus imipramine in painful polyneuropathy: a randomized, controlled trial. Neurology60 (8), 1284–1289 (2003).
   PubMed Web of Science ®Google Scholar
• Goldstein D, Lu Y, Detke M, Hudson J, Iyengar S, Demitrack M. Effects of duloxetine on painful physical symptoms associated with depression. Rychosomatics 45(1), 17–28 (2004).
   PubMed Web of Science ®Google Scholar
• JOSS J. Tricyclic antidepressant use in diabetic neuropathy. Ann. Pharmacother 33(9), 996–1000 (1999).
   PubMed Web of Science ®Google Scholar
• Ahmad M, Goucke C. Management strategies for the treatment of neuropathic pain in the elderly. Drugs Aging 19(12), 929–945 (2002).
   PubMed Web of Science ®Google Scholar
• Mallick R, Mangano R, Shrivastava R. Improvement in functionality with treatment of generalized social anxiety disorder: venlafaxine XR vs. placebo. J. Eur. Coll Neuropsychopharmacol 12 (Suppl. 3), S356 (2002).
   Google Scholar
• Montejo A, Llorca G, Izquierdo J, Rico- Villademoros E Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. Spanish working group for the study of psychotropic-related sexual dysfunction. j Clin. fisych. 62 (Suppl. 3), 10–21 (2001).
   Google Scholar
• Kennedy S, Eisfeld B, Dickens S, Bacchiochi J, Bagby R. Antidepressant-induced sexual dysfunction during treatment with moclobemide, paroxetine, sertraline and venlafaxine. j Clin. Rych. 61(4), 276–281 (2000).
   Google Scholar
• Trenque TDP, Frances C, Millart H, Germain M. Reports of withdrawal syndrome with the use of SSRIs: a case/ noncase study in the French pharmacovigilance database. Pharmacoepidemiol Drug Sal 11(4), 281–283 (2002).
   PubMed Web of Science ®Google Scholar
• Mayr B, Bonelli R. Severe headache with venlafaxine withdrawal. Ann. Pharmacother 37(7-8), 1145–1146 (2003).
   PubMed Web of Science ®Google Scholar
• Reeves R, Mack J, Beddingfield J. Shock- like sensations during venlafaxine withdrawal. Pharmacotherapy 23 (5), 678–681 (2003).
   PubMed Web of Science ®Google Scholar
• Haddad P. Antidepressant discontinuation syndromes. Drug- Sal 24(3), 183–197 (2001).
   PubMed Web of Science ®Google Scholar
• Vieta E, Martinez-Aran A, Goikolea J et al A randomized trial comparing paroxetineand venlafaxine in the treatment of bipolardepressed patients taking mood stabilizers.Clin. Psych. 63(6), 508–512 (2002).
   Google Scholar
• Albers L, Reist C, Vu R eta]. Effect of venlafaxine on imipramine metabolism. Psychiatry Res. 96(3), 235–243 (2000).
   PubMed Web of Science ®Google Scholar
• Ball S, Ahern D, Scatina J, Kao J. Venlafaxine: in vitro inhibition of CYP2D6 dependent imipramine and desipramine metabolism; comparative studies with selected SSRIs and effects on human hepatic CYP3A4, CYP2C9 and CYP1A2. Br. Clin. Pharmacol 43(6), 619–626 (1997).
   Google Scholar
• Amchin J, Zarycranski W, Taylor K, Albano D, Klockowski P Effect of venlafaxine on the pharmacokinetics of risperidone. j Clin. Pharmacol 39(3), 297–309 (1999).
   Web of Science ®Google Scholar
• Mekler G, Woggon B. A case of serotonin syndrome caused by venlafaxine and lithium. Phatmacopsychiatry 30 (6), 272–273 (1997).
   PubMed Web of Science ®Google Scholar
• Troy S, Parker V, Hicks D, Boudino F, Chiang S. Pharmacokinetic interaction between multiple-dose venlafaxine and single-dose lithium. J. Clin. Phatmacol 36(2), 175–181 (1996).
   Google Scholar
• Kudo S, Ishizaki T Pharmacokinetics of haloperidol: an update. Clin. Pharmacokinet. 37(6), 435–456 (1999).
   PubMed Web of Science ®Google Scholar
• Benazzi E Urinary retention with venlafaxine-haloperidol combination. Pharmacopsychiatry30(1), 27 (1997).
   Google Scholar
• Troy S, Rudolph R, Mayersohn M, Chiang S. The influence of cimetidine on the disposition kinetics of the antidepressant venlafaxine. j Clin. Pharmacol 38(5), 467–474 (1998).
   Web of Science ®Google Scholar
• Levin G, Nelson L, De Vane C, Preston S, Eisele G, Carson S. A pharmacokinetic drug—drug interaction study of venlafaxine and indinavir. PFhopharmacol Bull 35(2), 62–71 (2001).
   PubMedGoogle Scholar
• Hodgman M, Martin T, Krenzelok E. Serotonin syndrome due to venlafaxine and maintenance tranylcypromine therapy. Hum. Exp. Toxicol 16(1), 14–17 (1997).
   Google Scholar
• Gitlin M. Venlafaxine, monoamine oxidase inhibitors and the serotonin syndrome. Clin. PFhopharmacol 17(1), 66–67 (1997).
   PubMed Web of Science ®Google Scholar
• Brubacher J, Hoffman R, Lurin M. Serotonin syndrome from venlafaxine-tranylcypromine interaction. Vet. Hum. Toxic& 38(5), 358–361 (1996).
   Google Scholar